Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype

Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1–positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to e...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Richard G., Duchez, Anne-Claire, Simard, Trevor, Dhaliwal, Shan, Gillmore, Taylor, Di Santo, Pietro, Labinaz, Alisha, Ramirez, F. Daniel, Rasheed, Adil, Robichaud, Sabrina, Ouimet, Mireille, Short, Spencer, Clifford, Cole, Xiao, Fengxia, Lordkipanidzé, Marie, Burger, Dylan, Gadde, Suresh, Rayner, Katey J., Hibbert, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research - Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626902/
https://www.ncbi.nlm.nih.gov/pubmed/36337926
http://dx.doi.org/10.1016/j.jacbts.2022.05.002
Descripción
Sumario:Patients with established coronary artery disease remain at elevated risk of major adverse cardiac events. The goal of this study was to evaluate the utility of plasminogen activator inhibitor-1–positive platelet-derived extracellular vesicles as a biomarker for major adverse cardiac events and to explore potential underlying mechanisms. Our study suggests these extracellular vesicles as a potential biomarker to identify and a therapeutic target to ameliorate neointimal formation of high-risk patients.

Ejemplares similares